Report
The most in-depth report of the global nuclear medicine industry
Nuclear Medicine Series
Comprehensive data
Each report delivers hundreds of pages of exclusive insights across radionuclides, radiopharmaceuticals and company profiles, along with detailed market metrics.
Global market coverage
Our reports cover international trends, key players, and developments across all major regions.
Expert-driven analysis
Information is assessed and validated by experts with deep, long-standing experience in the nuclear medicine sector.
Versatile and targeted intelligence
Our reports merge technical, market, strategic, and financial insights to deliver value to all stakeholders in nuclear medicine.
Built on over a decade of intelligence
Backed by 12+ years of data, our reports offer historical market insights and yearly updates on key trends, developments, and performance.
Comprehensive data
Each report delivers hundreds of pages of exclusive insights across radionuclides, radiopharmaceuticals and company profiles, along with detailed market metrics.
Global market coverage
Our reports cover international trends, key players, and developments across all major regions.
Expert-driven analysis
Information is assessed and validated by experts with deep, long-standing experience in the nuclear medicine sector.
Versatile and targeted intelligence
Our reports merge technical, market, strategic, and financial insights to deliver value to all stakeholders in nuclear medicine
Built on over a decade of intelligence
Backed by 12+ years of data, our reports offer historical market insights and yearly updates on key trends, developments, and performance
Volume I - Current landscape of the nuclear medicine market
This report offers a comprehensive overview of the current global nuclear medicine market, providing insights on its evolving dynamics and trends. It includes detailed analyses of radionuclides and marketed radiopharmaceuticals, while also presenting thorough profiles of leading companies and institutions active in the field worldwide.
Report highlights – key contents
- Latest market trends and key events (2024–2025): an overview of recent industry developments, including key mergers and acquisitions activity, strategic partnerships and agreements shaping the nuclear medicine landscape, regulatory updates, product approvals and launches, investment trends, and emerging therapeutic applications across oncology, cardiology, and neurology.
- Strategic analysis of the radiopharmaceutical market: comprehensive insights into the market’s value chain, key growth drivers and restraints, regional segmentation, strategic mergers and acquisitions, and a long-term global outlook.
- Detailed radionuclides profiles: a robust analysis of 100+ radionuclides covering all radiation types for SPECT, PET and therapeutic use, describing their market availability, key suppliers, market challenges and competition landscape. The section also includes a comprehensive overview of all radionuclide production methods, encompassing neutron, proton, photon, alpha, and deuteron beam irradiation, complemented by a state-of-the-art analysis.
- Review of marketed radiopharmaceuticals: exhaustive analysis of products on the market, such as Pluvicto®, Lutathera®, FlyrcadoTM and Xofigo®, covering clinical applications, ongoing development programs, regional availability, pricing structures, and revenue insights.
- Company profiles: a comprehensive analysis of key manufacturers of PET, SPECT, and radiotherapeutic products including startups, private firms, and public research institutions, detailing their R&D pipelines, manufacturing capabilities, and strategic partnerships. These company profiles also includes financial analysis, management structure, and strategic positioning. The section covers all types of companies active in the sector, from small to large-size companies, having local or international activity, such as : Bayer, Novartis, Curium, Telix, Cardinal Health, ANSTO, NRG-PALLAS, BWXT, ITM, Lantheus, etc.
Why this report matters for your business?
This report is a must-have resource for professionals seeking to stay ahead of market shifts, navigate the competitive and regulatory landscape, and capitalize on strategic opportunities in the rapidly evolving nuclear medicine sector. By delivering a comprehensive blend of market intelligence, product analysis, and company profiling, it equips stakeholders with the insights necessary for informed, forward-looking decision-making.
Volume II - Strategic landscape of clinical radiopharmaceutical development
This report delivers a comprehensive analysis of radiopharmaceuticals currently in clinical development offering valuable insight into the next generation of innovations in nuclear medicine. It features in-depth evaluations of key radionuclides and presents detailed profiles of all major companies and institutions actively engaged in developing clinical-stage radiopharmaceuticals worldwide.
Report highlights – key contents:
- Strategic analysis of the radiopharmaceutical market: comprehensive insights into the market’s value chain, key growth drivers and restraints, regional segmentation, strategic mergers and acquisitions, and a long-term global outlook.
- Detailed radionuclides profiles: a robust analysis of 100+ radionuclides covering all radiation types for SPECT, PET and therapeutic use, describing their market availability, key suppliers, market challenges and competition landscape. The section also includes a comprehensive overview of all radionuclide production methods, encompassing neutron, proton, photon, alpha, and deuteron beam irradiation, complemented by a state-of-the-art analysis.
- Exclusive review of radiopharmaceuticals in clinical development: this exhaustive analysis covers 200+ radiopharmaceuticals under clinical development (Phase I/II/III) for both diagnostic and therapeutic products. This chapter describes the molecules that could enter the market within the next decade and shape the future of nuclear medicine for the benefit of patient. Each molecule, such as 225Ac-PSMA-617, 67Cu-SAR-bisPSMA, 18F-MK-6240, and 212Pb-VMT-α-NET, are described in details, with insights on their clinical applications, current phase of development, potential market relevance, competitive positioning, and biological/medical significance. Some transversal analysis per clinical indication are also included, providing a forward-looking view into where the radiopharmaceutical R&D field is headed.
- Company Profiles: a complete and detailed overview of all companies actively developing clinical-stage radiopharmaceuticals worldwide, including key players’ pipelines, partnerships, geographic focus, and innovation strategies. The section covers all types of companies developing molecules, such as: ABX-CRO, Actinium Pharmaceutical, Blue Earth Diagnostics, RayzeBio, Curasight, Clarity Pharmaceuticals, Orano Med, Sinotau pharmaceuticals, Peptidream, etc.
Volume 2 - Strategic landscape of clinical radiopharmaceutical development
This report delivers a comprehensive analysis of radiopharmaceuticals currently in clinical development offering valuable insight into the next generation of innovations in nuclear medicine. It features in-depth evaluations of key radionuclides and presents detailed profiles of all major companies and institutions actively engaged in developing clinical-stage radiopharmaceuticals worldwide.
Report highlights – key contents:
- Strategic analysis of the radiopharmaceutical market: comprehensive insights into the market’s value chain, key growth drivers and restraints, regional segmentation, strategic mergers and acquisitions, and a long-term global outlook.
- Detailed radionuclides profiles: a robust analysis of 100+ radionuclides covering all radiation types for SPECT, PET and therapeutic use, describing their market availability, key suppliers, market challenges and competition landscape. The section also includes a comprehensive overview of all radionuclide production methods, encompassing neutron, proton, photon, alpha, and deuteron beam irradiation, complemented by a state-of-the-art analysis.
- Exclusive review of radiopharmaceuticals in clinical development: this exhaustive analysis covers 200+ radiopharmaceuticals under clinical development (Phase I/II/III) for both diagnostic and therapeutic products. This chapter describes the molecules that could enter the market within the next decade and shape the future of nuclear medicine for the benefit of patient. Each molecule, such as 225Ac-PSMA-617, 67Cu-SAR-bisPSMA, 18F-MK-6240, and 212Pb-VMT-α-NET, are described in details, with insights on their clinical applications, current phase of development, potential market relevance, competitive positioning, and biological/medical significance. Some transversal analysis per clinical indication are also included, providing a forward-looking view into where the radiopharmaceutical R&D field is headed.
- Company Profiles: a complete and detailed overview of all companies actively developing clinical-stage radiopharmaceuticals worldwide, including key players’ pipelines, partnerships, geographic focus, and innovation strategies. The section covers all types of companies developing molecules, such as: ABX-CRO, Actinium Pharmaceutical, Blue Earth Diagnostics, RayzeBio, Curasight, Clarity Pharmaceuticals, Orano Med, Sinotau pharmaceuticals, Peptidream, etc.
Why this report matters for your business?
This report is essential for industry stakeholders, investors, and researchers, as it offers strategic insight into the rapidly advancing field of clinical-stage radiopharmaceuticals. It empowers readers to anticipate innovation trends, understand evolving therapeutic landscapes, and identify opportunities in the next generation of targeted nuclear medicine therapies.
Volume III - Preclinical landscape for next-generation radiopharmaceuticals
This report provides a detailed description and analysis of radiopharmaceuticals currently in preclinical and early-stage development, offering a clear view into the foundational stages of innovation in nuclear medicine. It also includes comprehensive profiles of all companies actively engaged in developing these emerging tracers and therapeutic agents, mapping the global landscape of early-stage radiopharma R&D.
Report highlights – key contents:
- Latest market trends and key events (2024–2025): An in-depth overview of recent developments across the nuclear medicine sector, including major mergers and acquisitions, strategic partnerships, regulatory changes, product launches, investment trends, and the rise of novel therapeutic applications in fields such as oncology, cardiology, and neurology.
- Exclusive review of radiopharmaceuticals in preclinical / early-stage development: this exhaustive analysis covers 600+ radiopharmaceuticals under preclinical development for both diagnostic and therapeutic products. This chapter describes the molecules that could reach clinical trials in the future. Each molecule, such as 211At-ATO-101, 212Pb-MP0712, 225Ac-ABD-147, and 68Ga-PNT6555 are described in details with insights on their mechanism of action, preclinical applications, current stage of development, relevant scientific publications, and an analysis of their potential clinical and commercial impact.
- Company Profiles: in-depth profiles of all companies developing early-stage radiopharmaceuticals worldwide, including organizational focus, R&D strategies, and pipeline assets. A dedicated section also highlights companies that were previously active in early-stage nuclear medicine research, offering historical context and tracking shifts in industry involvement. The section covers all types of companies developing molecules, such as: Abdera therapeutics, Aktis Oncology, ArtBio, Fusion Pharmaceuticals, Minerva Imaging, Nuclidium AG, Nihon Medi-Physics, Precirix, Perspective Therapeutics, etc.
- Complete index of radiopharmaceuticals (A–Z): a fully indexed reference guide of all radiopharmaceuticals covered in this volume, enabling quick access to information and comparison across candidates.
Why this report matters for your business?
This report serves as a comprehensive tool for understanding the early-stage innovation pipeline in nuclear medicine, with a focus on preclinical radiopharmaceutical development. By closely examining this emerging landscape, it not only supports R&D decision-making but also offers valuable foresight into how the market may evolve in the coming years. For example, monitoring the preclinical trends within the intensifying competition among next-generation alpha therapies such as 225Ac, 211At, and 212Pb provides a clear window into the scientific strengths, limitations, and strategic positioning of each isotope / molecules. Following these developments at the preclinical stage helps investors, R&D teams, and decision-makers assess where to allocate resources, anticipate competitive shifts, and align long-term strategies with the most promising therapeutic opportunities.
Get in touch to learn more about our reports and to receive their detailed table of contents
The most in-depth report of the global nuclear medicine industry
0
12th EDITION
0
PAGES
0
RADIOPHARMACEUTICALS
0
COMPANIES IN DETAIL
FAQ
About our reports
-
Who trusts and uses our market intelligence reports in nuclear medicine?
Our reports are trusted by a wide spectrum of stakeholders across the entire nuclear medicine value chain, supporting decisions from early research to clinical and strategic investment. Clients include radiopharmaceutical companies, radionuclide suppliers, equipment manufacturers, and operators irradiation facilities. Pharmaceutical and biotech firms integrating radiopharmaceuticals into oncology pipelines, as well as CRO/CDMOs providing manufacturing and regulatory support, also rely on our insights. Academic and research institutions, along with public health authorities and international bodies, apply our intelligence to policy and infrastructure planning. Our reports also support consulting firms, market analysts, and M&A stakeholders. Finally, institutional and private investors turn to us for reliable data to guide investment in radiopharmaceuticals and radionuclide supply markets.
-
How often is the Nuclear Medicine report updated, and how is it launched each year?
Each year, the latest edition of our Nuclear Medicine Market Report is released during the fourth quarter, in line with the EANM Annual Congress. The official publication typically coincides with the opening of the event, where attendees can preview the new edition directly at our booth. Our team is present on-site to engage with industry stakeholders, answer questions, and provide expert insight into the key developments, challenges, and trends that have shaped the past 12 months. This annual release ensures that our intelligence remains current, reflecting the latest data and strategic shifts across the global nuclear medicine landscape.
-
In what formats are your reports available?
Our reports are exclusively available in electronic format. Upon purchase, you will promptly receive a secure download link granting immediate access to the report in PDF format, which you may use within your organization in accordance with the terms of the license agreement
Client Reviews
Some endorsements from industry leaders
" A valuable reference work for nuclear medicine, whether on radioisotope production methods or on diagnostic and therapeutic aspects. We particularly appreciate the summary file of all treatments undergoing preclinical and clinical evaluation! "
Christine WAGNERManager R&D ORANO 
"For the first time we have access to a third party report addressing our specific market. This becomes an additional input to our internal market analysis which will eventually help shaping our road map and strategy. The Cyclotrons report presents quite detailed data both in terms of equipment types as well as relevant regional dynamics and data. We are happy to recommend this report to anyone acting in the field of medical cyclotrons and it is highly likely we will purchase future reports from MEDraysintell."
Uno Zetterberg Global Sales DirectorGE Healthcare 
"With his Proton Therapy report Paul-Emmanuel has given the industry eyes and ears. When these data were not available in the past, people were more or less making up their own numbers. The report is a must-read for market participants and investors, and I am looking forward to an annual update."
Jan Timmer Head of Marketing-Particle TherapyVarian Medical Systems, Inc. 
"At Urenco Isotopes, we believe that innovation in nuclear medicine can enrich lives. And that starts with access to reliable insights. MEDraysintell is a valuable partner in this mission, offering deep industry intelligence that helps us anticipate global needs and drive responsible growth. As we continue to expand the role of isotopes in diagnostics, therapy and beyond, we value platforms that support knowledge-sharing and shape the future of nuclear medicine."
Adriana CerusoBusiness Development Lead urenco 
"As a medium-sized pharmaceutical contract laboratory with more than 10 years of experience in the field of radiopharmacy, we are currently expanding our range of services in this area and making considerable investments in technology and personnel.
MEDraysintell's current report on nuclear medicine was an essential and valuable basis for our business plan. It contains a very good overall view of the industry and also good detailed information on individual players and products. In particular, we find the Executive Summary very effective and were able to use it very well for our purposes.
We have already recommended the report to some of our partners and are already looking forward to the 2019 edition."
Dr. Dirk Freitag-Stechl, M.B.A.CUP Laboratorien Dr. Freitag GmbH 
Client Reviews
Some endorsements from industry leaders
" A valuable reference work for nuclear medicine, whether on radioisotope production methods or on diagnostic and therapeutic aspects. We particularly appreciate the summary file of all treatments undergoing preclinical and clinical evaluation! "
Christine WAGNERManager R&D ORANO
"For the first time we have access to a third party report addressing our specific market. This becomes an additional input to our internal market analysis which will eventually help shaping our road map and strategy. The Cyclotrons report presents quite detailed data both in terms of equipment types as well as relevant regional dynamics and data. We are happy to recommend this report to anyone acting in the field of medical cyclotrons and it is highly likely we will purchase future reports from MEDraysintell."
Uno Zetterberg Global Sales DirectorGE Healthcare
"With his Proton Therapy report Paul-Emmanuel has given the industry eyes and ears. When these data were not available in the past, people were more or less making up their own numbers. The report is a must-read for market participants and investors, and I am looking forward to an annual update."
Jan Timmer Head of Marketing-Particle TherapyVarian Medical Systems, Inc.
"At Urenco Isotopes, we believe that innovation in nuclear medicine can enrich lives. And that starts with access to reliable insights. MEDraysintell is a valuable partner in this mission, offering deep industry intelligence that helps us anticipate global needs and drive responsible growth. As we continue to expand the role of isotopes in diagnostics, therapy and beyond, we value platforms that support knowledge-sharing and shape the future of nuclear medicine."
Adriana CerusoBusiness Development Lead urenco
"
MEDraysintell's current report on nuclear medicine was an essential and valuable basis for our business plan. It contains a very good overall view of the industry and also good detailed information on individual players and products. In particular, we find the Executive Summary very effective and were able to use it very well for our purposes.
We have already recommended the report to some of our partners and are already looking forward to the 2019 edition."
Dr. Dirk Freitag-Stechl, M.B.A.CUP Laboratorien Dr. Freitag GmbH
Other reports
Cyclotrons
This second edition of the Cyclotrons Report and Directory presents data collected up to 2020, identifying 1,484 cyclotrons worldwide used for producing medical radionuclides. Spanning 450 pages, it offers a global review of installed and sold cyclotrons, profiles 15 active manufacturers, and summarizes 12 former suppliers no longer in the market.
Proton Therapy
This seventh edition of the World Proton Therapy report features in a 380-page document a comprehensive review of the world market dynamics with an analysis of both past evolutions and future trends to the year 2030, and a detailed profile of 36 promoters, manufacturers or developers of proton and carbon therapy equipment with a directory of all PT facilities expected to become operational by 2025.
Brachytherapy
Second edition of the most comprehensive evaluation report and directory of brachytherapy, written by experts.This 340-page document provides a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world..